Jafron Biomedical Co Ltd Strategic Asset Allocation Index
Jafron Biomedical Co Ltd strategic asset allocation index. Jafron Biomedical Co Ltd (300529) has a Strategic Asset Allocation Index of 53.3% as of June 2023. Strategic assets (PP&E of CN¥1.73 Billion plus long-term investments of CN¥-) total CN¥1.73 Billion, measured against net assets of CN¥3.25 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Jafron Biomedical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Jafron Biomedical Co Ltd (2011–2021)
Strategic asset allocation index of Jafron Biomedical Co Ltd from 2011 to 2021. This chart shows how Jafron Biomedical Co Ltd's Strategic Asset Allocation Index has evolved across 11 annual periods from 2011 to 2021. As of June 2023, the index stands at 53.3%, representing strategic assets of CN¥1.73 Billion against net assets of CN¥3.25 Billion CNY.
Jafron Biomedical Co Ltd Strategic Asset Allocation Index by Year (2011–2021)
Jafron Biomedical Co Ltd strategic asset allocation index by year from 2011 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Jafron Biomedical Co Ltd from 2011 to 2021, covering 11 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Jafron Biomedical Co Ltd (300529) market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 37.6% | CN¥1.27 Billion | CN¥1.27 Billion | CN¥- | CN¥3.38 Billion | ▲ +5.7 pp |
| 2020 | 32.0% | CN¥905.51 Million | CN¥905.51 Million | CN¥- | CN¥2.83 Billion | ▲ +2.5 pp |
| 2019 | 29.5% | CN¥639.63 Million | CN¥639.63 Million | CN¥- | CN¥2.17 Billion | ▼ -2.4 pp |
| 2018 | 31.8% | CN¥548.19 Million | CN¥457.62 Million | CN¥90.57 Million | CN¥1.72 Billion | ▲ +8.4 pp |
| 2017 | 23.4% | CN¥325.55 Million | CN¥325.55 Million | CN¥- | CN¥1.39 Billion | ▲ +0.3 pp |
| 2016 | 23.1% | CN¥273.32 Million | CN¥273.32 Million | CN¥- | CN¥1.18 Billion | ▼ -23.0 pp |
| 2015 | 46.1% | CN¥260.16 Million | CN¥260.16 Million | CN¥- | CN¥564.06 Million | ▲ +1.6 pp |
| 2014 | 44.5% | CN¥201.28 Million | CN¥201.28 Million | CN¥- | CN¥452.42 Million | ▲ +9.0 pp |
| 2013 | 35.5% | CN¥135.03 Million | CN¥135.03 Million | CN¥- | CN¥380.12 Million | ▲ +12.7 pp |
| 2012 | 22.8% | CN¥66.33 Million | CN¥66.33 Million | CN¥- | CN¥290.84 Million | ▲ +16.0 pp |
| 2011 | 6.8% | CN¥14.73 Million | CN¥14.73 Million | CN¥- | CN¥215.57 Million | — |